“…However, several reports have shown that in some patients (approximately 20-30%), blast cells simultaneously express both myeloid and lymphoid markers (Drexler et al, 1991(Drexler et al, , 1993Buccheri et al, 1993). These cases were first called mixed-lineage leukaemias, with myeloid-antigen-positive acute lymphoblastic leukaemias (My+ ALL) (Sobol et al, 1987;Davey et al, 1988;Childs et al, 1989;Guyotat et al, 1990;Monpoux et al, 1990;Urbano-Ispizua et al, 1990;Hsu et al, 1991;Kurec et al, 1991;Pui et al, 1991;Kawamura & Tobinai, 1992;Kuerbitz et al, 1992;Hoelzer, 1994) being distinguished from lymphoid-antigen-positive acute myeloblastic leukaemias (Ly+ AML) (Das Gupta et al, 1987;Cross et al, 1988;Cuneo et al, 1992;Smith et al, 1992;Chen et al, 1993;Tien et al, 1993;Kawai et al, 1995;Lauria et al, 1995). They are now known as biphenotypic acute leukaemias (BAL) (Buccheri et al, 1993;Matutes et al, 1997;Uckun et al, 1997;Khalidi et al, 1998;Killick et al, 1999;Mi et al, 1999).…”